CB Insights 2020 Digital Health 150: Unlearn.AI named in List of Most Innovative Digital Health Startups

Today, CB Insights released its second annual Digital Health 150 ranking, and named Unlearn as one of the top 150 most promising private digital health companies in the world. Unlearn.AI was recognized for our achievements in clinical trials. 150 startups were highlighted across 12 categories, including Screening & Diagnostics, Drug Discovery, and Virtual Care Delivery. We are honored to be included in this impressive pool of visionary startups from 17 different countries, whose collective mission is to transform healthcare. 

Each year, through a rigorous, evidence-based approach, the CB Insights research team selects the Digital Health 150 from hundreds of applications based on several factors to evaluate the strength, novelty, and potential of each company. “We look forward to seeing the success of this year's class of the best in digital health," said CB Insights CEO Anand Sanwal.

Unlearn is thrilled to be recognized as a contributing member of the international community of pioneers in health. This is truly the era of innovation, where novel approaches to medicine and clinical research are actively being explored and embraced.

Our team has experienced a rewarding last few months, with continued, positive momentum in light of our Series A Funding announcement on April 20th. Unlearn will be presenting at Future of Health 2020 | CB Insights, September 23 - 25, where industry leaders will come together to discuss healthcare technologies, trends, and challenges we are facing today, and the solutions that will shape our path forward. We look forward to joining our fellow Digital Health 150 innovators in leading and navigating discussions that will accelerate the future of healthcare. We congratulate all of the companies who were nominated, and commend all of the startups that applied - together, we are moving the needle of change towards a healthier world.

Unlearn is the only company using AI to create Digital Twins to populate Intelligent Control Arms in clinical studies. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates virtual patients that are statistically matched to actual patients in clinical studies. This novel approach increases trial power and confidence, accelerates trial timelines, and enables patient level insights. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. Unlearn continues to have discussions with regulators, industry leaders, and other key stakeholders, and is seeking partners to help drive innovation in clinical research using AI.


Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Publications

Modeling Disease Progression in Mild Cognitive Impairment and Alzheimer's Disease with Digital Twins

Publications

Bayesian prognostic covariate adjustment

Publications

Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer's Disease Trials (CTAD 2020)

We showed that digital twins could reduce the number of control subjects required in the analysis to achieve equivalent results to an analysis of the actual subjects.
Our novel method - Bayesian prognostic covariate adjustment - is a Bayesian analysis that draws on the strengths of the prognostic model approach.
Here, we have demonstrated that a particular type of generative model (i.e., CRBMs) can be used to accurately model disease progression for patients with MCI or AD.